share_log

Critical Analysis: Heska (NASDAQ:HSKA) & Cardio Diagnostics (NASDAQ:CDIO)

Critical Analysis: Heska (NASDAQ:HSKA) & Cardio Diagnostics (NASDAQ:CDIO)

批判分析:心臟 (納斯達克:HSKA) & 心肺診斷 (納斯達克:CDIO)
Financial News Live ·  2023/01/15 02:41

Cardio Diagnostics (NASDAQ:CDIO – Get Rating) and Heska (NASDAQ:HSKA – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

心臟診斷(納斯達克:CDIO-GET評級)和赫斯卡(納斯達克:HSKA-GET評級)都是小盤醫療公司,但哪種投資更好?我們將根據這兩家公司的收益、盈利能力、風險、分析師建議、股息、估值和機構所有權等方面的實力進行比較。

Institutional & Insider Ownership

機構與內部人持股

77.3% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 99.0% of Heska shares are owned by institutional investors. 11.0% of Heska shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cardio Diagnostics 77.3%的股份由機構投資者持有。相比之下,赫斯卡99.0%的股份由機構投資者持有。赫斯卡11.0%的股份由內部人士持有。強大的機構持股表明,大型基金管理公司、捐贈基金和對衝基金相信,一隻股票有望實現長期增長。

Get
到達
Cardio Diagnostics
心臟診斷學
alerts:
警報:

Profitability

盈利能力

This table compares Cardio Diagnostics and Heska's net margins, return on equity and return on assets.

此表比較了Cardio Diagnostics和Heska的淨利潤率、股本回報率和資產回報率。

Net Margins Return on Equity Return on Assets
Cardio Diagnostics N/A N/A N/A
Heska -6.26% 0.09% 0.06%
淨利潤率 股本回報率 資產回報率
心臟診斷學 不適用 不適用 不適用
赫斯卡 -6.26% 0.09% 0.06%

Analyst Ratings

分析師評級

This is a breakdown of current ratings and target prices for Cardio Diagnostics and Heska, as provided by MarketBeat.
這是MarketBeat提供的Cardio Diagnostics和Heska的當前評級和目標價格的細目。
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardio Diagnostics 0 0 0 0 N/A
Heska 1 0 3 0 2.50
銷售評級 保持評級 購買評級 強勁的買入評級 評級分數
心臟診斷學 0 0 0 0 不適用
赫斯卡 1 0 3 0 2.50

Cardio Diagnostics currently has a consensus price target of $8.00, suggesting a potential upside of 525.00%. Heska has a consensus price target of $123.00, suggesting a potential upside of 56.77%. Given Cardio Diagnostics' higher possible upside, equities research analysts clearly believe Cardio Diagnostics is more favorable than Heska.

心臟診斷公司目前的共識目標價為8.00美元,暗示潛在上漲525.00%。赫斯卡的一致目標價為123.00美元,暗示潛在上行空間為56.77%。鑑於Cardio Diagnostics較高的可能上行空間,股票研究分析師顯然認為Cardio Diagnostics比Heska更有利。

Earnings & Valuation

收益與估值

This table compares Cardio Diagnostics and Heska's top-line revenue, earnings per share and valuation.

此表比較了Cardio Diagnostics和Heska的營收、每股收益和估值。

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cardio Diagnostics N/A N/A -$140,000.00 N/A N/A
Heska $253.74 million 3.35 -$1.15 million ($1.57) -49.97
總收入 價格/銷售額比 淨收入 每股收益 市盈率
心臟診斷學 不適用 不適用 -$140,000.00 不適用 不適用
赫斯卡 2.5374億美元 3.35 -115萬美元 ($1.57) -49.97

Cardio Diagnostics has higher earnings, but lower revenue than Heska.

心臟診斷公司的收益比赫斯卡高,但收入比赫斯卡低。

Summary

摘要

Heska beats Cardio Diagnostics on 6 of the 9 factors compared between the two stocks.

赫斯卡在兩隻股票比較的9個因素中有6個擊敗了Cardio Diagnostics。

About Cardio Diagnostics

關於Cardio診斷公司

(Get Rating)

(獲取評級)

Cardio Diagnostics Holdings, Inc., a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.

心臟診斷控股公司是一家生物技術公司,開發和商業化基於表觀遺傳學的心血管疾病臨牀測試。它提供Epi+Gen,這是一種為期三年的症狀性冠心病(CHD)風險評估測試,針對包括心臟病發作在內的CHD事件。該公司成立於2017年,總部位於伊利諾伊州芝加哥。

About Heska

關於赫斯卡

(Get Rating)

(獲取評級)

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was founded in 1988 and is based in Loveland, Colorado.

赫斯卡公司為美國、加拿大、墨西哥、澳大利亞、法國、德國、意大利、馬來西亞、西班牙和瑞士的狗和貓保健市場銷售獸醫和動物健康診斷和特種產品。公司提供用於血液化學和電解質分析的Element DC、Element DCX、Element DC5x;用於血液化學和電解質分析的Element RC、Element RCX和Element RC3X化學系統;用於測量血細胞、血小板計數和血紅蛋白水平的Element HT5和Element Vet ABC Plus;Element POC血氣和電解質分析儀;Element I免疫診斷分析儀;Element COAG和Element AIM獸醫分析儀。該公司還提供HeskaView Telecytotology,提供臨牀自動化顯微鏡載片掃描和計算設備;靜脈輸液泵;數字放射硬件和移動數字放射產品;超聲波系統;基於Web的圖像存儲解決方案Cloudbank;用於檢測與動物傳染病和寄生蟲病相關的抗原和抗體的護理點產品;用於治療犬心蟲感染、蛔蟲和鈎蟲感染的Tri-Heart Plus咀嚼片;以及過敏產品和服務,包括ALLERCEPT明確過敏原面板,以及治療針劑或滴劑。此外,該公司還為其他動物保健公司提供一系列牛疫苗、生物和醫藥產品,以及包括研究、許可、生產、標籤和包裝在內的交鑰匙服務,以及驗證支持和分銷服務。它通過電話銷售隊伍和第三方分銷商向獸醫銷售產品,並通過貿易展、平面廣告和其他分銷關係銷售產品。該公司前身為Paravax, 並於1995年更名為赫斯卡公司。該公司成立於1988年,總部設在科羅拉多州的洛夫蘭。

Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

接收《心臟診斷日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Cardio Diagnostics和相關公司的最新新聞和分析師評級的每日摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論